



## Metastatic Breast Cancer: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

1.0  
NCPD

Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN®

- NCPD credit
- ILNA points

Virtual Visiting Faculty Meeting

### STATEMENT OF NEED

Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 6% present with metastatic disease, and up to 30% with no initial lymph node involvement eventually develop metastatic disease. Women with MBC have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 27%.

### TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with MBC

### LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Identify predictive and prognostic markers that can tailor treatment selection and goals to individual patients with metastatic breast cancer (MBC)
- Evaluate the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC
- Assess strategies to manage treatment-related adverse events, promote adherence to therapy, and ensure patient-centered MBC care

### FACULTY

Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN®  
(Chair)  
Nurse Practitioner  
Memorial Sloan Kettering Cancer Center

Sarah Donahue, MPH, NP, AOCNP® (Speaker)  
Nurse Practitioner  
Carol Franc Buck Breast Cancer Center  
University of California San Francisco

Marissa Marti, APRN, AGNP-C, AOCNP®  
Nurse Practitioner  
Baylor Charles A. Sammons Cancer Center

Constance Visovsky, PhD, RN, ACNP, FAAN  
Professor and Leona Hughes Endowed Chair  
University of South Florida

### ABOUT THE SPEAKER

Sarah Donahue, MPH, NP, AOCNP®, is a nurse practitioner at the Carol Franc Buck Breast Cancer Center of the Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco. She specializes in the treatment of patients with early stage and metastatic breast cancer being treated with chemotherapy, hormone therapy, or targeted therapy. Ms. Donahue has authored or coauthored numerous publications focused on the treatment and management of patients with breast cancer.

### ACCREDITATION

Provided by



i3 Health is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.



A maximum of 1.0 contact hours may be earned by learners who successfully complete this nursing continuing professional development activity.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hours.

### REGISTRATION

There is no fee to participate in or claim NCPD credit for this activity.

Please note that i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

### Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA *PRA Category 1 Credit™* from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

### REQUIREMENTS FOR CREDIT

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

## DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS

i3 Health endorses the standards of the ANCC that require everyone in a position to control the content of an NCPD activity to disclose all financial relationships with commercial interests that are related to the content of the NCPD activity. NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect NCPD content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and commercial interests:

### Faculty

- Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN®, has no relevant financial relationships to disclose
- Sarah Donahue, MPH, NP, AOCNP®, discloses that she serves on an advisory board or panel for Novartis and Sanofi, that she serves on the speaker's bureau for Seagen, and that she receives salary or contractual services from Genentech
- Marissa Marti, APRN, AGNP-C, AOCNP®, discloses that she serves on an advisory board or panel for Novartis and Puma
- Constance Visovsky, PhD, RN, ACNP, FAAN, has no relevant financial relationships to disclose

### Planners and Managers

The i3 Health planners, reviewers, and managers have nothing to disclose.

### UNAPPROVED USE DISCLOSURE

i3 Health requires NCPD faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for nursing continuing professional development and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

## AGENDA

- I. Pre-Activity Assessment
- II. MBC: Scope of the Problem
- III. Case Icebreaker: Tailoring Therapeutic Strategies to Individual Patients
- IV. Overview of Clinicopathologic Evaluation, Genetic Testing, and Staging
- V. Update on Emerging Evidence and Evolving Treatment Standards
  - a. HER2-positive disease
  - b. HER2-negative disease (eg, hormone receptor-positive, BRCA-mutated)
  - c. Triple-negative disease
- VI. Managing Adverse Events and Promoting Adherence to Therapy
- VII. Answering Common Patient Questions About Their Prognosis and Treatment
- VIII. Case Icebreaker: Optimizing Treatment Experiences and Ensuring Patient-Centered Care
- IX. Educational Resources to Share With Patients With MBC
- X. Key Learning Takeaways/Participant Q&As
- XI. Post-Activity Assessment
- XII. 4-Week Clinical Pearls Follow-Up Email

## DISCLAIMER

The information provided at this NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

## SUNSHINE ACT

Per the Physician Payments Sunshine Act, i3 Health is required by law to report to CMS any transfers of value (including food and beverage) provided to a covered recipient during a commercially supported educational event. Effective January 1, 2020, Physician Assistants, Nurse Practitioners, and Clinical Nurse Specialists are considered "covered recipients". All NPs and CNSs who would like to participate in the provided meal will be asked to provide all required information for reporting purposes.

## COMMERCIAL SUPPORT

This educational activity is supported by independent educational grants from Bristol-Myers Squibb and Eisai.

Aggregate participant data will be shared with commercial supporters of this activity.

## DOWNLOAD THE SPEAKER SLIDES

<https://i3health.com/metastatic-breast-cancer-2#speaker-slides>

## AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact i3 Health prior to the live event at 973-928-8085 or support@i3Health.com.

## CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3Health.com.